Pantothenic Acid
| Evidence Level: L5 | Predicted Indications: 9 |
Table of Contents
- Pantothenic Acid
Pantothenic Acid: Congenital prothrombin deficiency
One-Sentence Summary
Pantothenic acid (vitamin B5) is a coenzyme A precursor; its original indications are ascorbic acid deficiency and scurvy. The TxGNN model predicts it may be effective for congenital prothrombin deficiency, but this is a model prediction only, with 0 clinical trials and 0 publications supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Congenital prothrombin deficiency |
| TxGNN Prediction Score | 0.9996 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (1 of 1) – CDSCO approval status is not included in this data |
| Number of Listed Products | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, pantothenic acid is a B vitamin and the precursor of coenzyme A, which takes part in lipid and energy metabolism.
Congenital prothrombin deficiency is a monogenic defect of coagulation factor II. Pantothenic acid is not known to affect prothrombin synthesis or function, so no mechanistic link can be identified. The very high score (0.9996) reflects a computational association only and is not backed by any trial or publication.
Other Predictions Considered
Eight further predictions were reviewed. None has trial evidence.
| Predicted Indication | Score | Evidence Level | Assessment |
|---|---|---|---|
| Ochronosis disorder | 0.9978 | L5 | No known role in homogentisic acid metabolism; Hold |
| Glycerol metabolism disease | 0.9977 | L5 | Only a loose link through coenzyme A; the retrieved papers are incidental metabolomics studies; Hold |
| Folic acid deficiency anemia | 0.9960 | L4 | Plausible nutritional link, but evidence is old and indirect; research question |
| Uterine inflammatory disease | 0.9914 | L5 | One 2026 mouse study; no human data; research question |
| Xanthogranulomatous pyelonephritis | 0.9910 | L5 | No rationale; Hold |
| Urinary tract infection | 0.9910 | L5 | Retrieved papers are unrelated; Hold |
| Gonococcal urethritis | 0.9910 | L5 | No antibacterial role; Hold |
| Ureaplasma urethritis | 0.9910 | L5 | No antibacterial role; Hold |
Of these, folic acid deficiency anemia and uterine inflammatory disease have the most plausible rationale. Folate is the established treatment for the former, so pantothenic acid would at most be adjunctive.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
For the top-ranked prediction (congenital prothrombin deficiency), currently no related literature is available.
The literature found for the next most relevant predictions is listed below.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 41223999 | 2026 | Preclinical (mouse) | Mucosal Immunology | Pantothenic acid alleviated vagotomy-induced endometrial injury in mice (uterine inflammatory disease) |
| 3724048 | 1986 | Review | Laboratory Animal Science | Review of nutritional deficiency anemias in nonhuman primates, including pantothenic acid and folic acid deficiency |
| 21021037 | 1946 | Historical study | Nutrition Reviews | Anemia and granulocytopenia in relation to pantothenic acid and folic acid deficiencies |
| 21929634 | 2011 | Review | Maternal & Child Nutrition | Fortified foods in pregnancy and lactation and their effect on nutritional status |
The five papers retrieved for glycerol metabolism disease are metabolomics or microbiota profiling studies. The two papers retrieved for urinary tract infection are a case series on a multivitamin transporter deficiency and a zoledronic acid case report. These appear to be incidental keyword matches and are not listed as evidence.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 153595 | Nervic-Plus Injection (Unimarck Healthcare Ltd) | Vial of 2 ml injection | Not stated |
Safety Considerations
- Knowledge-graph contraindication signals (from drug-disease relationships in the knowledge graph, not from label text): kidney disease, pyoureter, sickle cell anemia, hereditary persistence of fetal hemoglobin, primary hyperoxaluria, hereditary hemochromatosis, hemosiderosis, iron metabolism disease, Wilson disease.
No package insert warnings, contraindications or drug interaction data were available. Please refer to the package insert for full safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The top-ranked prediction, congenital prothrombin deficiency, has no mechanistic link, no clinical trials and no literature. It is supported only by a model score. Of the alternatives, folic acid deficiency anemia and uterine inflammatory disease are worth follow-up as research questions, but neither has human evidence.
To proceed, the following is needed:
- Package insert warnings and contraindications from the Indian regulator (a blocking gap for safety screening)
- Mechanism of action data for pantothenic acid
- Human clinical evidence for any candidate indication, with priority on folic acid deficiency anemia and uterine inflammatory disease
- Review of the knowledge-graph contraindication signals, especially kidney disease and iron metabolism disorders
- Route compatibility assessment: the only registered product is an injectable multi-ingredient-style brand, and its approved indication text is not available
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.